Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)

Cushing’s disease is associated with increased morbidity and mortality. Osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid, sustained mean urinary free cortisol (mUFC) normalization in Cushing’s disease patients in two Phase III studies (LINC 3, NCT02180217; LINC 4, NCT02697734)....

Full description

Bibliographic Details

Published in:	Endocrine Journal
Main Authors:	Akira Shimatsu, Beverly MK Biller, Maria Fleseriu, Rosario Pivonello, Eun Jig Lee, Rattana Leelawattana, Jung Hee Kim, Rama Walia, Yerong Yu, Zhihong Liao, Andrea Piacentini, Alberto M Pedroncelli, Peter J Snyder
Format:	Article
Language:	English
Published:	The Japan Endocrine Society 2024-12-01
Subjects:	cushing’s syndrome clinical trial efficacy safety race
Online Access:	https://www.jstage.jst.go.jp/article/endocrj/71/12/71_EJ24-0153/_html/-char/en